Nature-Branded Journals Announce First Open-Access Deal

The agreement will enable authors at eligible German institutes to publish an estimated 400 open-access papers each year in Springer Nature journals from the Nature line of titles.

Written byMax Kozlov
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM,
OLLO

Springer Nature, the parent company of the Nature suite of journals, will allow researchers affiliated with around 120 German institutions to publish an estimated 400 open-access papers in these titles annually starting in 2021.

The deal, announced yesterday (October 20), will be offered to institutions that currently subscribe to Nature journals. The first to sign up is the Max Planck Society, an association of 86 research institutes. The deal will be “an enormous opportunity for scientists in Germany,” as well as an opportunity for researchers elsewhere to build on their scientific findings, Klaus Blaum, vice president of the Max Planck Society’s Scientific Council for Chemistry, Physics and Technology, says in a statement.

Springer Nature signed a similar agreement—to date, the world’s largest transformative agreement, in which publishers and research institutions agree to a contract that contains elements geared towards increasing open access—with a consortium of more than ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Max is a science journalist from Boston. Though he studied cognitive neuroscience, he now prefers to write about brains rather than research them. Prior to writing for The Scientist as an editorial intern in late 2020 and early 2021, Max worked at the Museum of Science in Boston, where his favorite part of the job was dressing in a giant bee costume and teaching children about honeybees. He was also a AAAS Mass Media Fellow, where he worked as a science reporter for the St. Louis Post-Dispatch. Read more of his work at www.maxkozlov.com.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies